Advancing inducible gene-inactivation systems to explore synthetic lethality
Open Access
- 9 January 2026
- journal article
- Published by Oxford University Press (OUP) in NAR Cancer
- Vol. 8 (1)
Abstract
Synthetic lethality offers opportunities to identify therapeutic targets for cancer research, facilitating the development of targeted tumour therapy protocols. However, current gene knockout approaches may cause compensatory changes in cellular function and, often, RNAi does not align with the ideal time window for studies and can be inconsistent, limiting the study of molecular interactions, especially when the disruption of two genes causes cell death. To circumvent this problem, we developed the IGIS (Inducible Gene-Inactivation Systems) platform, which uses transient or targeted integration of tetracycline-regulated gene-silencing constructs into human cell lines and fluorescent markers, permitting precise timing of gene inactivation, avoiding transfection variability, and enabling follow-up assays. The applicability of the IGIS systems was validated by investigating the functional interplay between the BRCA1 and RAD18 genes. Combining IGIS with cell survival, DNA fibre, BrdU alkaline comet assays, and pRPA immunostaining, we show that BRCA1 and RAD18 work in different pathways in replication-fork restart and post-replicative gap filling, and thus combined loss of these factors leads to accumulation of ssDNA gaps and replication catastrophe. This synthetic-lethal interaction study with our newly developed IGIS method highlights RAD18-dependent tolerance mechanisms as potential therapeutic vulnerabilities in BRCA-deficient tumours.Keywords
Funding Information
- National Research, Development, and Innovation Office (2020-1.1.5)
- European Union’s Horizon 2020 Research and Innovation Program (739593)
This publication has 114 references indexed in Scilit:
- Adaptive TherapyCancer Research, 2009
- Human HLTF functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitinationProceedings of the National Academy of Sciences, 2008
- Human SHPRH is a ubiquitin ligase for Mms2–Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigenProceedings of the National Academy of Sciences, 2006
- Ubiquitylation of yeast proliferating cell nuclear antigen and its implications for translesion DNA synthesisProceedings of the National Academy of Sciences, 2006
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- EUKARYOTIC TRANSLESION SYNTHESIS DNA POLYMERASES: Specificity of Structure and FunctionAnnual Review of Biochemistry, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Inhibition of p53 by Lentiviral Mediated sh RNA Abrogates G1 Arrest and Apoptosis in Retinal Pigmented Epithelial Cell LineCell Cycle, 2005
- Yeast DNA Repair Proteins Rad6 and Rad18 Form a Heterodimer That Has Ubiquitin Conjugating, DNA Binding, and ATP Hydrolytic ActivitiesJournal of Biological Chemistry, 1997